An unjust arrest at Starbucks. A national conversation. Now? A cash reward of $1.

In April, two black men were arrested and led out of a Philadelphia Starbucks for absolutely no reason.  

On April 12, Rashon Nelson and Donte Robinson arrived at the coffee shop a few minutes before a business meeting. Nelson asked to use the bathroom but was denied because he hadn't bought anything. He returned to the table where he and Robinson were waiting for their associate. They were approached, The Washington Post reports, by the white manager only moments later. Her message: Buy something.

By now you probably know what happened next: Unsatisfied with whatever answer she was given, the manager called 911 and asked for help. Two men, she told the dispatcher, were refusing to buy something or leave. Nelson and Robinson were handcuffed and escorted out of the cafe by policemen. Then, they were taken to jail.  


A recording of the arrest instantly went viral, with the public responding in outrage to both the manager's actions (how many of us have sat in Starbucks for hours without ordering so much as a water?) and the police's response.    

The pair recollected the traumatic incident on ABC news:

Nelson and Robinson have now reached a settlement with the city. It's a study in healing, forgiveness, and inspiration.

Though the two men could have sued Philadelphia — especially after both the mayor and the police commissioner admitted that the situation hadn't been handled correctly — they agreed to a settlement no one expected. Each man accepted a symbolic $1 from the city. In addition, The Washington Post reports, they've asked Philadelphia to fund a $200,000 grant to support area high school students with entrepreneurial dreams. According to ABC News, the mens' arrest records will be expunged. Starbucks, for their part, will pay for Nelson and Robinson's college education as part of a mostly undisclosed financial settlement. The pair will meet with former Attorney General Eric Holder, who's assisting Starbucks in creating a training on racial bias.

The injustice was horrific. For many it brought two things into stark relief for the first time.

One: Racial bias and discrimination happen on a moment-to-moment basis in America.

While some still argue that Nelson and Robinson must have done something wrong in order to have been escorted out by police (just check the comments on any news story about their arrest), the reality is the only thing the two men were guilty of was being on the wrong end of someone's prejudice. And that kind of prejudice makes what happened to Nelson and Robinson an everyday occurrence.  

Shortly after the Nelson and Robinson's story blew up, a piece in The New York Times detailed the many incidents of racial bias that had occurred in the Rittenhouse Square area of Philadelphia — where the men had been arrested.

"Although black people account for just 3% of the residents in that police subdistrict, they made up two-thirds of the people stopped by the police in the first half of 2017, according to figures collected by the American Civil Liberties Union," The Times reported.  

Protestors at a Philadelphia Starbucks rally against the discrimination of Nelson and Robinson. Photo by Mark Makela/Getty Images.

Two: We must all work to end this type of commonplace oppression.

After the president and CEO of Starbucks met with the men to offer an apology, Starbucks announced that it would close 8,000 of its stores on May 29 for "racial bias training." While one day is hardly enough time to transform the crisis of systemic racism, the training is one step in ensuring that what the manager did doesn't happen again.

"What Starbucks is doing shows an understanding that to dismiss one employee as a crazy racist is to ignore the context in which that individual learns beliefs, pushes them on others, and abuses power. Using this as a teachable moment company-wide also sets an example," author Sara Benincasa wrote in a tweet.  

Nelson and Robinson's hope? That something positive comes from such a terrible incident.

"We thought long and hard about it, and we feel like this is the best way to see that change that we want to see," Robinson, said of the settlement. "It's not a right-now thing that's good for right now, but I feel like we will see the true change over time."

For John Shults and Joy Morrow-Nulton, the COVID-19 pandemic brought more than just health threats and lockdown woes. For the two 95-year-olds, it also held something remarkable—another chance at romance.

Both Shults and Morrow-Nulton had been married twice and widowed twice, but they were determined to find love again. They met in May of 2019, brought together by Morrow-Nulton's 69-year-old son, John Morrow.

"She was cute, I'll tell you that," Shultz told the New York Times of their first meeting. "And she was smart and she had a delightful sense of humor. And she smiled at me."

Shultz asked her to lunch a few more times before it became crystal clear to Morrow-Nulton that he was on a mission to date her.

Keep Reading Show less

For John Shults and Joy Morrow-Nulton, the COVID-19 pandemic brought more than just health threats and lockdown woes. For the two 95-year-olds, it also held something remarkable—another chance at romance.

Both Shults and Morrow-Nulton had been married twice and widowed twice, but they were determined to find love again. They met in May of 2019, brought together by Morrow-Nulton's 69-year-old son, John Morrow.

"She was cute, I'll tell you that," Shultz told the New York Times of their first meeting. "And she was smart and she had a delightful sense of humor. And she smiled at me."

Shultz asked her to lunch a few more times before it became crystal clear to Morrow-Nulton that he was on a mission to date her.

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."